

**THE UNIVERSITY OF WESTERN ONTARIO
 BIOHAZARDOUS AGENTS REGISTRY FORM**
 Approved Biohazards Subcommittee: September 25, 2009
 Biosafety Website: www.uwo.ca/humanresources/biosafety/

This form must be completed by each Principal Investigator holding a grant administered by the University of Western Ontario or in charge of a laboratory/facility where the use of Level 1, 2 or 3 biohazardous agents is described in the laboratory or animal work proposed. The form must also be completed if any work is proposed involving animals carrying zoonotic agents infectious to humans or involving plants, fungi, or insects that require Public Health Agency of Canada (PHAC) or Canadian Food Inspection Agency (CFIA) permits.

This form must be updated at least every 3 years or when there are changes to the biohazards being used.

Containment Levels will be established in accordance with Laboratory Biosafety Guidelines, 3rd edition, 2004, Public Health Agency of Canada (PHAC) or Containment Standards for Veterinary Facilities, 1st edition 1996, Canadian Food Inspection Agency (CFIA).

Completed forms are to be returned to Occupational Health and Safety, (OHS), (Support Services Building, Room 4190) for distribution to the Biohazard Subcommittee. For questions regarding this form, please contact the Biosafety Officer at extension 81135 or biosafety@uwo.ca. If there are changes to the information on this form (excluding grant title and funding agencies), contact Occupational Health and Safety for a modification form. See website: www.uwo.ca/humanresources/biosafety/

PRINCIPAL INVESTIGATOR GARY SHAW
 SIGNATURE *Gshaw*
 DEPARTMENT BIOCHEMISTRY
 ADDRESS MSB 306
 PHONE NUMBER x 84021
 EMERGENCY PHONE NUMBER(S) 519 858 2728
 EMAIL gshaw1@uwo.ca

Location of experimental work to be carried out: Building(s) MSB Room(s) 312

*For work being performed at Institutions affiliated with the University of Western Ontario, the Safety Officer for the Institution where experiments will take place must sign the form prior to its being sent to the University of Western Ontario Biosafety Officer (See Section 12.0, Approvals).

FUNDING AGENCY/AGENCIES: CIHR, Canadian Cancer Society
 GRANT TITLE(S): Identification and mechanisms of novel Sioc protein interactions
Structures and mechanisms of proteins involved in Parkinsons Disease
Structure and mechanism of class II E2 enzymes in ubiquitylation

PLEASE ATTACH A BRIEF DESCRIPTION OF YOUR WORK THAT EXPLAINS THE BIOHAZARDS USED AND HOW THEY WILL BE USED. PROJECTS SUBMITTED WITHOUT A SUMMARY WILL NOT BE REVIEWED. A GRANT SUMMARY PAGE MAYBE ADEQUATE IF IT PROVIDES SUFFICIENT DETAIL ABOUT EACH BIOHAZARD USED.

Names of all personnel working under Principal Investigators supervision in this location:

<u>Kathryn Barber</u>	<u>Ben Cook</u>
<u>Don Spratt</u>	<u>Chee Wang Ng</u>
<u>Brian Dempsey</u>	<u>Steven Beasley</u>
<u>Mariana Silvestry</u>	<u>Ventzi Christova</u>
<u>Atoosa Rezaianpour</u>	<u>Nicole Marlatt</u>
<u>Chantal Forristal</u>	<u>Stephanie Serniwicka</u>

1.0 Microorganisms

1.1 Does your work involve the use of biological agents? YES NO
 (including but not limited to bacteria and other microorganisms, viruses, prions, parasites or pathogens of plant or animal origin)? If no, please proceed to Section 2.0

Do you use microorganisms that require a permit from the CFIA? YES NO

If YES, please give the name of the species. _____

What is the origin of the microorganism(s)? _____

Please describe the risk (if any) of escape and how this will be mitigated:

Please attach the CFIA permit.

Please describe any CFIA permit conditions:

1.2 Please complete the table below:

Name of Biological agent(s)*	Is it known to be a human pathogen? YES/NO	Is it known to be an animal pathogen? YES/NO	Is it known to be a zoonotic agent? YES/NO	Maximum quantity to be cultured at one time? (in Litres)	Source/ Supplier	PHAC or CFIA Containment Level
E. coli - BL21	<input type="radio"/> Yes <input checked="" type="radio"/> No	<input type="radio"/> Yes <input checked="" type="radio"/> No	<input type="radio"/> Yes <input checked="" type="radio"/> No	12 L	Invitrogen	<input checked="" type="radio"/> 1 <input type="radio"/> 2 <input type="radio"/> 3
	<input type="radio"/> Yes <input type="radio"/> No	<input type="radio"/> Yes <input type="radio"/> No	<input type="radio"/> Yes <input type="radio"/> No			<input type="radio"/> 1 <input type="radio"/> 2 <input type="radio"/> 3
	<input type="radio"/> Yes <input type="radio"/> No	<input type="radio"/> Yes <input type="radio"/> No	<input type="radio"/> Yes <input type="radio"/> No			<input type="radio"/> 1 <input type="radio"/> 2 <input type="radio"/> 3
	<input type="radio"/> Yes <input type="radio"/> No	<input type="radio"/> Yes <input type="radio"/> No	<input type="radio"/> Yes <input type="radio"/> No			<input type="radio"/> 1 <input type="radio"/> 2 <input type="radio"/> 3

*Please attach a Material Safety Data Sheet or equivalent from the supplier.

2.0 Cell Culture

2.1 Does your work involve the use of cell cultures? YES NO
 If no, please proceed to Section 3.0

2.2 Please indicate the type of primary cells (i.e. derived from fresh tissue) that will be grown in culture:

Cell Type	Is this cell type used in your work?	Source of Primary Cell Culture Tissue	AUS Protocol Number
Human	<input type="radio"/> Yes <input type="radio"/> No		Not applicable
Rodent	<input type="radio"/> Yes <input type="radio"/> No		
Non-human primate	<input type="radio"/> Yes <input type="radio"/> No		
Other (specify)	<input type="radio"/> Yes <input type="radio"/> No		

* DESCRIPTION MUST BE ATTACHED TO THIS FORM OR PROJECT WILL NOT BE REVIEWED*

2.3 Please indicate the type of established cells that will be grown in culture in:

Cell Type	Is this cell type used in your work?	Specific cell line(s)*	Supplier / Source
Human	<input type="radio"/> Yes <input type="radio"/> No		
Rodent	<input type="radio"/> Yes <input type="radio"/> No		
Non-human primate	<input type="radio"/> Yes <input type="radio"/> No		
Other (specify)	<input type="radio"/> Yes <input type="radio"/> No		

*Please attach a Material Safety Data Sheet or equivalent from the supplier. (For more information, see www.atcc.org)

2.4 For above named cell types(s) indicate PHAC or CFIA containment level required 1 2 3

3.0 Use of Human Source Materials

3.1 Does your work involve the use of human source materials? YES NO
If no, please proceed to Section 4.0

3.2 Indicate in the table below the Human Source Material to be used.

Human Source Material	Source/Supplier /Company Name	Is Human Source Material Infected With An Infectious Agent? YES/NO	Name of Infectious Agent (If applicable)	PHAC or CFIA Containment Level (Select one)
Human Blood (whole) or other Body Fluid		<input type="radio"/> Yes <input type="radio"/> No <input type="radio"/> Unknown		<input type="radio"/> 1 <input type="radio"/> 2 <input type="radio"/> 3
Human Blood (fraction) or other Body Fluid		<input type="radio"/> Yes <input type="radio"/> No <input type="radio"/> Unknown		<input type="radio"/> 1 <input type="radio"/> 2 <input type="radio"/> 3
Human Organs or Tissues (unpreserved)		<input type="radio"/> Yes <input type="radio"/> No <input type="radio"/> Unknown		<input type="radio"/> 1 <input type="radio"/> 2 <input type="radio"/> 3
Human Organs or Tissues (preserved)		Not Applicable		Not Applicable

4.0 Genetically Modified Organisms and Cell lines

4.1 Will genetic modifications be made to the microorganisms, biological agents, or cells described in Sections 1.0 and 2.0? YES NO If no, please proceed to Section 5.0

4.2 Will genetic modification(s) involving plasmids be done? YES, complete table below NO

Bacteria Used for Cloning *	Plasmid(s) *	Source of Plasmid	Gene Transfected	Describe the change that results
JM109	pET pGEX pcDNA pDNR pJexpress	commercial		

* Please attach a Material Data Sheet or equivalent if available.

4.3 Will genetic modification(s) involving viral vectors be made? YES, complete table below NO

Virus Used for Vector Construction	Vector(s) *	Source of Vector	Gene(s) Transduced	Describe the change that results

* Please attach a Material Safety Data Sheet or equivalent.

4.4 Will genetic sequences from the following be involved?

- ◆ HIV YES, please specify _____ NO
- ◆ HTLV 1 or 2 or genes from any Level 1 or Level 2 pathogens YES, specify _____ NO
- ◆ SV 40 Large T antigen YES NO
- ◆ E1A oncogene YES NO
- ◆ Known oncogenes YES, please specify _____ NO
- ◆ Other human or animal pathogen and or their toxins YES, please specify _____ NO

4.5 Will virus be replication defective? YES NO

4.6 Will virus be infectious to humans or animals? YES NO

4.7 Will this be expected to increase the containment level required? YES NO

5.0 Human Gene Therapy Trials

5.1 Will human clinical trials be conducted involving a biological agent? YES NO
(including but not limited to microorganisms, viruses, prions, parasites or pathogens of plant or animal origin)
If no, please proceed to Section 6.0

5.2 If YES, please specify which biological agent will be used: _____
Please attach a full description of the biological agent.

5.2 Will the biological agent be able to replicate in the host? YES NO

5.3 How will the biological agent be administered? _____

5.4 Please give the Health Care Facility where the clinical trial will be conducted: _____

5.5 Has human ethics approval been obtained? YES, number: _____ NO PENDING

6.0 Animal Experiments

6.1 Will live animals be used? YES NO If no, please proceed to section 7.0

6.2 Name of animal species to be used _____

6.3 AUS protocol # _____

6.4 Will any of the agents listed in section 4.0 be used in live animals YES, specify: _____ NO

6.5 Will the agent(s) be shed by the animal: YES NO, please justify:

* DESCRIPTION MUST BE ATTACHED TO THIS FORM OR PROJECT WILL NOT BE REVIEWED*

10.0 Plants Requiring CFIA Permits

10.1 Do you use plants that require a permit from the CFIA? YES NO
If no, please proceed to Section 11.0

10.2 If YES, please give the name of the species. _____

10.3 What is the origin of the plant? _____

10.4 What is the form of the plant (seed, seedling, plant, tree...)? _____

10.5 What is your intention? Grow and maintain a crop "One-time" use

10.6 Do you do any modifications to the plant? YES NO
If yes, please describe: _____

10.7 Please describe the risk (if any) of loss of the material from the lab and how this will be mitigated:

10.8 Is the CFIA permit attached? YES NO
If NO, please forward the permit to the Biosafety Officer when available.

10.9 Please describe any CFIA permit conditions:

11.0 Import Requirements

11.1 Will any of the above agents be imported? YES, please give country of origin _____
If no, please proceed to Section 12.0 NO

11.2 Has an Import Permit been obtained from HC for human pathogens? YES NO

11.3 Has an import permit been obtained from CFIA for animal or plant pathogens? YES NO


11.4 Has the import permit been sent to OHS? YES, please provide permit # _____ NO

12.0 Training Requirements for Personnel Named on Form

All personnel named on the above form who will be using any of the above named agents are required to attend the following training courses given by OHS:

- ◆ Biosafety
- ◆ Laboratory and Environmental/Waste Management Safety
- ◆ WHMIS (Western or equivalent)
- ◆ Employee Health and Safety Orientation

As the Principal Investigator, I have ensured that all of the personnel named on the form who will be using any of the biohazardous agents in Sections 1.0 to 9.0 have been trained.

SIGNATURE  _____

*** DESCRIPTION MUST BE ATTACHED TO THIS FORM OR PROJECT WILL NOT BE REVIEWED***


13.0 Containment Levels

11.1 For the work described in sections 1.0 to 9.0, please indicate the highest HC or CFIA Containment Level required. 1 2 3

13.2 Has the facility been certified by OHS for this level of containment?
 YES, permit # if on-campus BIO-UWO-4103
 NO, please certify
 NOT REQUIRED for Level 1 containment

14.0 Procedures to be Followed

14.1 As the Principal Investigator, I will ensure that this project will follow the Western Biosafety Guidelines and Procedures Manual for Containment Level 1 & 2 Laboratories (and the Level 3 Facilities Manual for Level 3 projects). I will ensure that UWO faculty, staff and students working in my laboratory have an up-to-date Hazard Communication Form, found at <http://www.wph.uwo.ca/>

SIGNATURE  Date: 4 MARCH 2010

14.2 Please describe additional risk reduction measures will be taken beyond containment level 1, 2, or 3 measures, that are unique to this agent.

14.3 Please outline what will be done if there is an exposure to the biohazards listed, such as a needlestick injury:

15.0 Approvals

UWO Biohazard Subcommittee: SIGNATURE: _____
Date: _____

Safety Officer for Institution where experiments will take place: SIGNATURE: _____
Date: _____

Safety Officer for University of Western Ontario (if different from above): SIGNATURE: _____
Date: _____

Approval Number: _____ Expiry Date (3 years from Approval): _____

Special Conditions of Approval:

Project Description for Biohazardous Agents Registry

Investigator: Gary Shaw

Projects Covered

- A. Identification and Mechanisms of Novel S100 Protein Interactions (CIHR, 2009-2014)
- B. Structures and Mechanisms of Proteins Involved in Parkinson's Disease (CIHR, 2009-2014)
- C. Structure and Mechanism of Class II E2 Enzymes in Ubiquitylation

Brief Description of Biohazards Used

In all three projects a variety of plasmids are used as carriers for genes in non-infectious *E. coli* bacteria for the purpose of expressing specific proteins. Genes for a variety of S100 proteins including, but not limited to, S100B, S100A1, S100A11, S100A8, S100A9 and S100A10 are expressed in Project A. Genes for parkin, HOIL-1, S5a, UbcH7, UbcH8 are expressed in Project B. In Project C, genes for the proteins HIP2, Ubc1, cdc34 are expressed. In all cases, amino acid substitutions are, or might be made, for the purposes of structural and biophysical characterization of the resulting protein.

Identification and Mechanisms of Novel S100 Protein Interactions

Most S100 proteins are dimeric, *EF-hand* proteins that undergo calcium-induced conformational changes and interact with a variety of target proteins to trigger a biological response. However, the functional characterization of many S100 proteins is tempered by a lack of cellular data due to the transient nature of the calcium-bound S100 protein *in vivo*. In the past 2 years new and exciting *in vivo* data has unequivocally shown two major functions of the S100 proteins are (1) membrane vesiculation and repair and, (2) translocation of the G-coupled receptors to the plasma membrane. In (1) at least four proteins are required – S100A10, dysferlin, annexin A2 and the plasma membrane protein AHNAK – to bind to and close a lesion in a plasma membrane. In (2) S100A10 interacts with the third intracellular loop from the serotonin receptor 5HT1B and S100A10 knock-out mouse studies show a depression-like phenotype. S100B forms a complex with the same loop of dopamine receptors D2S and D2L and mediates signaling whose dysfunction leads to neurological disorders. *Importantly, all of these in vivo observations have occurred with calcium-free S100 proteins.* In addition, a new association between S100A11 and annexin A6 has also been identified that shows multiple binding sites indicating this protein-protein pair must have a unique role in membrane vesiculation events.

These observations have raised new questions about the biological roles and mechanisms of S100 proteins including: (1) can a constitutively active S100 protein be designed that would function *in vivo*, (2) how does S100A10 coordinate the assembly of dysferlin, AHNAK and annexin A2 to repair a membrane lesion, (3) what are the structures and mechanisms used by the serotonin and dopamine receptors for S100A10 and S100B recognition – can the S100B interaction be modulated by calcium binding and, (4) how does S100A11 recruit and position annexin A6 to control membrane fusion.

The **hypotheses** we wish to test are:

- (1) Removal of S100A11 calcium sensitivity promotes a constitutively active conformation.
- (2) S100A10 controls the assembly and disassembly of the dysferlin complex.
- (3) S100A10 and S100B act as delivery proteins for serotonin and dopamine receptors to the plasma membrane that is mediated by annexin A2.
- (4) S100A11 forms a novel structure with annexin A6 that can coordinate membrane fusion.

The **specific aims** and **research plan** are:

- (1) Engineer hybrid apo-S100A11 proteins based on the “open” structure of S100A10. Assess the structures of these and use them to identify and confirm *in vivo* targets for S100A11,
- (2) Identify the mechanism S100A10 uses to form a membrane repair complex that includes annexin A2, AHNAK and dysferlin. Determine the structure of this complex. Identify how the dysferlin V67D mutation disrupts complex formation.
- (3) Determine the affinities and structures of S100A10 and S100B for the serotonin 5HT1B and dopamine D2L/D2S intracellular loops respectively. Identify the S100-receptor selectively and understand how annexin A2 modulates the S100-receptor interaction,
- (4) Identify the binding regions of annexin A6 and mechanism used by S100A11 for interaction.

Our work will provide **significant advances** including:

- (1) Development of a constitutively active S100A11 protein to be used for *in vivo* experiments,
- (2) The first structural model of a protein complex that modulates membrane repair. A rationale for the dysferlin V67D mutation in limb girdle muscular dystrophy will be developed,
- (3) The determinants of dopamine and serotonin receptor recognition for S100 proteins will be established allowing future drug design towards depression and neurological disorders,
- (4) A new mechanism for membrane vesiculation used by S100A11 to recruit annexin proteins.

Structures and Mechanisms of Proteins Involved in Parkinson's Disease

Ubiquitylation is the central pathway for the trafficking of signaling proteins and removal of unfolded proteins from the cell. A defining step in this pathway is the passage of ubiquitin (Ub) or an ubiquitin-like (SUMO, ISG15) protein from an E2 enzyme (ie. UbcH8) to a substrate, complexed with an adaptor E3 ligase protein. Parkin is a key E3 ligase responsible for autosomal recessive juvenile parkinsonism (AR-JP), a common form of familial Parkinson's disease. This unique 465-residue protein comprises an N-terminal "ubiquitin-like" domain (UbLD) and a C-terminal RBR region consisting of two RING domains separated by an In-Between-RING domain (IBR). Missense mutations identified throughout parkin coincide with the disease. During the past grant period, we developed methods for parkin expression/purification, determined the 3D structure of parkin's IBR domain, and identified a new Zn-binding domain in parkin. We are now poised to use these novel findings to address the mechanisms of parkin-mediated protein degradation and trafficking including: (1) what mechanism does parkin use to distinguish association with the proteasome vs. substrates, (2) how does parkin recognize the E2 protein UbcH8 to ubiquitylate proteins, (3) how do UbcH8 and parkin facilitate ISG15 transfer in addition to Ub labeling, (4) what are the novel protein targets for parkin ubiquitylation and how are functions modified, and (5) what is the overall architecture of parkin and how do AR-JP mutations alter this? These questions will be addressed using biophysical, in vivo techniques and parkin carrying missense mutations to uncover the structures, interactions and mechanisms of this E3 ligase in neurodegeneration.

The **hypotheses** to be tested are:

- (i) the UbLD forms distinctive, non-identical complexes with the proteasome vs. substrates,
- (ii) UbcH8 binding and ubiquitylation activity requires the IBR-RING2 domain from parkin,
- (iii) specific interactions occur between UbcH8, ISG15 and parkin to facilitate ISG15 transfer,
- (iv) parkin selects and ubiquitylates cellular targets critical for dopamine neuron survival,
- (v) a unique arrangement of parkin's UbLD and RING domains accounts for ubiquitylation.

The **specific aims and research plan** for this project are;

- (i) determine 3D structures of parkin complexes with regions from the S5a proteasomal subunit and substrates ataxin-3 and Eps15,
- (ii) identify the interactions and 3D structure of the parkin-UbcH8 complex,
- (iii) explore the kinetics of Ub and ISG15 transfer by UbcH8 and parkin; determine structures of UbcH8-ISG15 and UbcH8-Ub,
- (iv) identify biological targets for parkin by protein array and TAP tag methods; examine sub-cellular localization and functional outcomes,
- (v) identify the spatial relationship and architecture of the UbLD and RBR regions of parkin.

This work will provide **significant findings** including:

- (i) the first structures showing how parkin distinguishes proteasome vs substrate proteins,
- (ii) the residues and surfaces on parkin allowing its interaction and function with UbcH8,
- (iii) a structural rationale and mechanism for ISG-15 recognition and manipulation by parkin,
- (iv) the interactome, subcellular localization and novel functions for parkin,
- (v) the first 3D model of parkin allowing its mechanisms for ubiquitylation, and detrimental affects of missense mutations in AR-JP to be established.

10. DETAILED SCIENTIFIC ABSTRACT / RÉSUMÉ SCIENTIFIQUE DÉTAILLÉ

Responses must be limited to one page. Refer to the *2006 Grant Application Guide* for specific instructions regarding the format to be used for this section. / Les réponses doivent être limitées à une page. Consultez le *Guide de demande de subvention de 2006* pour obtenir les directives spécifiques ayant trait au format à utiliser pour cette section.

Shaw, Gary S.

Department of Biochemistry

The University of Western Ontario

Structure and Mechanism of Class II E2 Enzymes in Ubiquitylation

Keywords/Technical Terms: ubiquitin (Ub), conjugating enzymes, protein degradation, nuclear magnetic resonance (NMR) spectroscopy

The uncontrollable growth and proliferation of cancer cells is a result of defects in the cell cycle, the central process that insures proteins are phosphorylated and dephosphorylated in a timely and specific manner as required for transcription and translation events. This requires a delicate balance between the synthesis of cyclins, cyclin-dependent kinases (Cdk1, Cdk2) and kinase inhibitors (p21, p27) that perform the various signal transduction tasks of the cycle and the degradation of these same proteins to limit their function. It is now well-established that the ubiquitin-mediated proteolysis pathway (ubiquitylation) is the key process for optimizing the levels of most cell cycle proteins. For example, the G1-S transition of cell cycle is marked by Cdk2 activation as the cell prepares for DNA synthesis. This step is controlled, not by increased expression of Cdk2, but rather the degradation of the Cdk2 inhibitor p27 by an E3-ligase SCF complex that includes the E2-conjugating enzyme CDC34. In prostate, breast and colorectal cancers inappropriate reduction of p27 levels by over-active SCF ubiquitylation has been established based on mouse and clinical studies.

The E2 enzyme CDC34 is a central protein involved in the ubiquitylation pathway that accepts ubiquitin (Ub) from an E1 enzyme and forms an unstable Ub~E2 thioester intermediate, either separately or as part of the SCF complex. Although many elegant biochemical studies and 3D structures of E1-E2 and E2-E3 complexes are available, the mechanism whereby these enzymes build polyubiquitin chains necessary to label a protein targeted for degradation is largely unknown. This is particularly true for the class II E2 conjugating enzymes such as CDC34, Hip2 and yeast Ubc1. These proteins are characterized by unique C-terminal extensions that are required for polyubiquitin chain formation and allow them to assemble these Ub polymers even in the absence of an E3 protein. We have recently determined the first structure of a class II conjugating protein (Ubc1) and have developed a novel method to create stable Ub-E2 intermediate protein complexes. We will now use this experience to focus on the E2 enzymes CDC34, Hip2 and Ubc1 and gain a detailed structural understanding of their structures and mechanisms of polyubiquitin chain assembly.

In particular we will address the following questions;

- 1) How does the Ub~E2 thioester intermediate promote polyubiquitin chain assembly?
- 2) How do class II E2 enzymes such as Hip2, CDC34 and Ubc1 build polyubiquitin chains ?
- 3) How are K48- and K63-linked polyubiquitin chain recognized by Hip2 and Ubc1 ?

To answer these questions we will:

- 1) Determine the 3D structures of the Ub-E2 intermediates for CDC34, Hip2 and Ubc1 to identify how these unique class II E2 proteins direct ubiquitination.
- 2) Identify how CDC34, Hip2, and Ubc1 facilitate the transfer of a thioester-bound Ub to an acceptor Ub.
- 3) Determine the structure and provide a rationale for the involvement of the C-termini for Hip2 and Ubc1 for both the recruiting and assembly of K48- and K63-linked ubiquitin chains.

We anticipate these experiments will provide us with detailed structures and mechanisms showing how these proteins build polyubiquitin chains. Further we expect the differences observed between the structures and their interactions with assembled polyubiquitin chains will establish how a protein such as CDC34 efficiently labels p27 for proteasomal degradation. These details will be important in understanding how new therapies against cancer can be designed that target the E2 proteins.

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Product code 500149
Product name BL21 (DE3) One Shot

Company/Undertaking Identification

INVITROGEN CORPORATON
5791 VAN ALLEN WAY
PO BOX 6482
CARLSBAD, CA 92008
760-603-7200

INVITROGEN CORPORATION
2270 INDUSTRIAL STREET
BURLINGTON, ONT
CANADA L7P 1A1
800-263-6236

GIBCO PRODUCTS
INVITROGEN CORPORATION
3175 STALEY ROAD P.O. BOX 68
GRAND ISLAND, NY 14072
716-774-6700

24 hour Emergency Response (Transport): 866-536-0631
301-431-8585
Outside of the U.S. ++1-301-431-8585

2. COMPOSITION/INFORMATION ON INGREDIENTS**Hazardous/Non-hazardous Components**

Chemical Name	CAS-No	Weight %
Glycerol	56-81-5	10-30

3. HAZARDS IDENTIFICATION**Emergency Overview**

The product contains no substances which at their given concentration, are considered to be hazardous to health

Form
Liquid

3. HAZARDS IDENTIFICATION

Principle Routes of Exposure/

Potential Health effects

Eyes	No information available
Skin	No information available
Inhalation	No information available
Ingestion	No information available

Specific effects

Carcinogenic effects	No information available
Mutagenic effects	No information available
Reproductive toxicity	No information available
Sensitization	No information available

Target Organ Effects

No information available

HMIS

Health	0
Flammability	0
Reactivity	0

4. FIRST AID MEASURES

Skin contact	Wash off immediately with plenty of water
Eye contact	Rinse immediately with plenty of water, also under the eyelids, for at least 15 minutes
Ingestion	Never give anything by mouth to an unconscious person
Inhalation	Move to fresh air
Notes to physician	Treat symptomatically.

5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	Dry chemical
Special protective equipment for firefighters	Wear self-contained breathing apparatus and protective suit

6. ACCIDENTAL RELEASE MEASURES

Personal precautions	Use personal protective equipment
Methods for cleaning up	Soak up with inert absorbent material.

7. HANDLING AND STORAGE

Handling	No special handling advice required
Storage	Keep in properly labelled containers

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Occupational exposure controls

Exposure limits

Chemical Name	OSHA PEL (TWA)	OSHA PEL (Ceiling)	ACGIH OEL (TWA)	ACGIH OEL (STEL)
Glycerol	15 mg/m ³ total dust 5 mg/m ³ respirable fraction	-	10 mg/m ³	-

Engineering measures Ensure adequate ventilation, especially in confined areas

Personal protective equipment

Respiratory protection	In case of insufficient ventilation wear suitable respiratory equipment
Hand protection	Protective gloves
Eye protection	Safety glasses with side-shields
Skin and body protection	Lightweight protective clothing.
Hygiene measures	Handle in accordance with good industrial hygiene and safety practice
Environmental exposure controls	Prevent product from entering drains.

9. PHYSICAL AND CHEMICAL PROPERTIES

General Information

Form Liquid

Important Health Safety and Environmental Information

Boiling point/range	°C No data available	°F No data available
Melting point/range	°C No data available	°F No data available
Flash point	°C No data available	°F No data available
Autoignition temperature	°C No data available	°F No data available
Oxidizing properties	No information available	
Water solubility	No data available	

10. STABILITY AND REACTIVITY

Stability	Stable under normal conditions.
Materials to avoid	No information available
Hazardous decomposition products	No information available
Polymerization	Hazardous polymerisation does not occur.

11. TOXICOLOGICAL INFORMATION

Acute toxicity

Chemical Name	LD50 (oral, rat/mouse)	LD50 (dermal, rat/rabbit)	LC50 (inhalation, rat/mouse)
Glycerol	12600 mg/kg (Rat)	10 g/kg (Rabbit)	570 mg/m ³ (Rat)

Principle Routes of Exposure/

Potential Health effects

Eyes	No information available
Skin	No information available
Inhalation	No information available
Ingestion	No information available

Specific effects

Carcinogenic effects	No information available
Mutagenic effects	No information available
Reproductive toxicity	No information available

Sensitization No information available

Target Organ Effects No information available

12. ECOLOGICAL INFORMATION

Ecotoxicity effects No information available.

Mobility No information available.

Biodegradation No information available.

Bioaccumulation No information available

13. DISPOSAL CONSIDERATIONS

Dispose of in accordance with local regulations

14. TRANSPORT INFORMATION

IATA

Proper shipping name Not classified as dangerous in the meaning of transport regulations

Hazard Class No information available

Subsidiary Class No information available

Packing group No information available

UN-No No information available

15. REGULATORY INFORMATION

International Inventories

Chemical Name	TSCA	PICCS	ENCS	DSL	NDSL	AICS
Glycerol	Listed	Listed	Listed	Listed	-	Listed

U.S. Federal Regulations

SARA 313

This product is not regulated by SARA.

Clean Air Act, Section 112 Hazardous Air Pollutants (HAPs) (see 40 CFR 61)

This product does not contain HAPs.

U.S. State Regulations

Chemical Name	Massachusetts - RTK	New Jersey - RTK	Pennsylvania - RTK	Illinois - RTK	Rhode Island - RTK
Glycerol	Listed	-	Listed	-	Listed

California Proposition 65

This product does not contain chemicals listed under Proposition 65

WHMIS hazard class:

Non-controlled

This product has been classified according to the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR

16. OTHER INFORMATION

This material is sold for research and development purposes only. It is not for any human or animal therapeutic or clinical diagnostic use. It is not intended for food, drug, household, agricultural, or cosmetic use. An individual technically qualified to handle potentially hazardous chemicals must supervise the use of this material.

The above information was acquired by diligent search and/or investigation and the recommendations are based on prudent application of professional judgment. The information shall not be taken as being all inclusive and is to be used only as a guide. All materials and mixtures may be present unknown hazards and should be used with caution. Since Invitrogen Corporation cannot control the actual methods, volumes, or conditions of use, the Company shall not be held liable for any damages or losses resulting from the handling or from contact with the product as described herein. **THE INFORMATION IN THIS MSDS DOES NOT CONSTITUTE A WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE.**

End of Safety Data Sheet



MATERIAL SAFETY DATA SHEET

EMERGENCY TELEPHONE NO. 1-800-632-5227
OTHER INFORMATION CALLS 1-978-927-5054
FAX: 1-978-921-1350
INTERNET e-mail: info@neb.com

Strain
#E4107S

SECTION 1 - PRODUCT

Product Name: *E. coli* K12 JM109

SECTION 2—COMPOSITION/ INFORMATION ON INGREDIENT

Strains supplied by NEB are all derivatives of *E. coli* K12, *E. coli* B or hybrids of these two strains. *E. coli* K12 and B are nonpathogenic isolates. K12 is the standard nonpathogenic host, exempt from the NIH Recombinant DNA Advisory Committee (RAC) guidelines (1).

E. coli B has also been shown to lack common pathogenicity-related sequences (2).

References:

1. Federal Register, (1986) Vol. V1: 88, 6952–16985.
2. Kuhnert, P., Hacker, I. Muldorfer, A. P. Burnens, J. Nicolet, and J. Frey (1997). Detection system for Escherichia coli-specific virulence genes.: absence of virulence determinants in B and C strains. Appl. Environ. Microbiol. 63(2): 703– 709.

Order Number

Customer Number

1. Product and Company Identification

Supplier	Manufactured by EMD Biosciences, Inc. 441 Charmany Drive Madison, WI 53719 (608)238-6110 (800)207-0144 FAX: (608)238-1388 P.O. Box 12087 La Jolla, CA 92039-2087 (858)450-5558 (800)854-3417 FAX: (858)453-3552	Catalog #	70777
		In Case of Emergency	Call Chemtrec® (800)424-9300 (within U.S.A.) (703)527-3887 (outside U.S.A.)

Product name pET Expression System 28

2. Composition and Information on Ingredients

Ingredient Name	CAS No.	Product No.	EU Symbol	R-Phrases
Induction Control E		RC0039	-	-
pET-28a(+) DNA		RC0041	-	-
BL21 Glycerol Stock		RC0131	-	-
BL21(DE3) Glycerol Stock		RC0262	-	-
BL21(DE3)pLysS Glycerol Stock		RC0263	-	-
pET-28b(+) DNA		RC0324	-	-
pET-28c(+) DNA		RC0325	-	-

Note: See section 8 for occupational exposure limits and section 11 for LC50/LD50 information.

3. Hazards Identification

Primary Hazards and Critical Effects	:	RC0039, RC0041, RC0131, RC0262, RC0263, RC0324, RC0325	No specific hazard.
Physical/Chemical hazards	:		Not applicable.
Human Health Hazards	:		Not applicable.
Environmental Hazards	:		Not applicable.

4. First Aid Measures

Inhalation	:	RC0039, RC0041, RC0131, RC0262, RC0263, RC0324, RC0325	If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical attention.
Ingestion	:	RC0039, RC0041, RC0131, RC0262, RC0263, RC0324, RC0325	Do NOT induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious person. If large quantities of this material are swallowed, call a physician immediately.
Skin Contact	:	RC0039, RC0041, RC0131, RC0262, RC0263, RC0324, RC0325	In case of contact, immediately flush skin with plenty of water. Remove contaminated clothing and shoes. Wash clothing before reuse. Thoroughly clean shoes before reuse. Get medical attention.
Eye Contact	:	RC0039, RC0041, RC0131, RC0262, RC0263, RC0324, RC0325	In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. Get medical attention.
Notes to Medical Doctor	:		Not available.

5. Fire-Fighting Measures

Extinguishing Media	:	Use foam or all purpose dry chemicals to extinguish.
Fire-Fighting Procedures	:	Fire fighters should wear positive pressure self-contained breathing apparatus (SCBA) and full turnout gear.
Fire/Explosion Hazards	:	Not applicable.
Hazardous Decomposition Products	:	Not available.

6. Accidental Release Measures

Personal Precautions	:	Immediately contact emergency personnel. Keep unnecessary personnel away. Use suitable protective equipment (Section 8). Follow all fire fighting procedures (Section 5).
Environmental Precautions and Clean-up Methods	:	If emergency personnel are unavailable, contain spilled material. For small spills add absorbent (soil may be used in the absence of other suitable materials) scoop up material and place in a sealed, liquid-proof container for disposal. For large spills dike spilled material or otherwise contain material to ensure runoff does not reach a waterway. Place spilled material in an appropriate container for disposal. Minimize contact of spilled material with soils to prevent runoff to surface waterways.

Note: See section 1 for emergency contact information and section 13 for waste disposal.

7. Handling and Storage

Handling	:	RC0039, RC0041, RC0131, RC0262, RC0263, RC0324, RC0325	Wash thoroughly after handling.
Storage	:		Keep container tightly closed. Keep container in a cool, well-ventilated area.
Packaging Materials	:		Use original container.

8. Exposure Controls and Personal Protection

Occupational Exposure Limits

Ingredient Name

RC0039
RC0041
RC0131
RC0262
RC0263
RC0324
RC0325

Occupational Exposure Limits

Not available.
Not available.
Not available.
Not available.
Not available.
Not available.
Not available.

Engineering Controls	:	RC0039, RC0041, RC0131, RC0262, RC0263, RC0324, RC0325	No special containment is required. Local exhaust ventilation should be provided.
----------------------	---	--	---

Personal Protective Equipment

Respiratory System	:	RC0039, RC0041, RC0131, RC0262, RC0263, RC0324, RC0325	Use appropriate respiratory protection if there is the potential to exceed the exposure limit(s).
Skin and Body	:	RC0039, RC0041, RC0131, RC0262, RC0263, RC0324, RC0325	Work uniform or laboratory coat.
Hands	:	RC0039, RC0041, RC0131, RC0262, RC0263, RC0324, RC0325	Use chemical resistant, impervious gloves. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits). Appropriate techniques should be used to remove potentially contaminated clothing.
Eyes	:	RC0039, RC0041, RC0131, RC0262, RC0263, RC0324, RC0325	Safety glasses. Goggles, face shield, or other full-face protection if potential exists for direct exposure to aerosols or splashes.

9. Physical and Chemical Properties

Kit Components

39258: 1 x 0.2 ml Induction Control E (RC0039)
39386: 1 x 0.2 ml BL21 Glycerol Stock (RC0131)
39387: 1 x 0.2 ml BL21(DE3) Glycerol Stock (RC0262)
39388: 1 x 0.2 ml BL21(DE3)pLysS Glycerol Stock (RC0263)
39864: 1 x 10 ug pET-28a(+) DNA (RC0041)
39865: 1 x 10 ug pET-28b(+) DNA (RC0324)
39866: 1 x 10 ug pET-28c(+) DNA (RC0325)

Flash Point

Not available.

10. Stability and Reactivity

Stability : RC0041, RC0131, RC0262, RC0263, RC0324, RC0325 The product is stable.
Conditions and Materials to Avoid : Not available.
Hazardous Decomposition Products : Not available.

11. Toxicological Information

Toxicity Data

<u>Ingredient Name</u>	<u>Test</u>	<u>Result</u>	<u>Route</u>	<u>Species</u>
RC0039	Not available.	Not available.	Not available.	Not available.
RC0041	Not available.	Not available.	Not available.	Not available.
RC0131	Not available.	Not available.	Not available.	Not available.
RC0262	Not available.	Not available.	Not available.	Not available.
RC0263	Not available.	Not available.	Not available.	Not available.
RC0324	Not available.	Not available.	Not available.	Not available.
RC0325	Not available.	Not available.	Not available.	Not available.

Routes of Entry : Not available.

Acute Effects

Inhalation : Not available.
Ingestion : Not available.
Skin Contact : Not available.
Eye Contact : Not available.

Chronic Effects

Adverse Effects : Not available.
Target Organs : Not available.
Carcinogenic Effects : Not available.
Mutagenic Effects : Not available.
Developmental and Teratogenic Effects : Not available.
Reproductive Effects : Not available.

Other Information : RC0039, RC0041, RC0131, RC0262, RC0263, RC0324, RC0325 Repeated or prolonged exposure is not known to aggravate medical condition.

12. Ecological Information

Ecotoxicity Data

<u>Ingredient Name</u>	<u>Species</u>	<u>Period</u>	<u>Result</u>
RC0039	Not available.	Not available.	Not available.
RC0041	Not available.	Not available.	Not available.
RC0131	Not available.	Not available.	Not available.
RC0262	Not available.	Not available.	Not available.
RC0263	Not available.	Not available.	Not available.
RC0324	Not available.	Not available.	Not available.
RC0325	Not available.	Not available.	Not available.

13. Disposal Consideration

Waste Handling and Disposal : Waste must be disposed of in accordance with federal, state and local environmental control regulations.

14. Transport Information

Air
IATA-DGR Class : Not controlled under IATA.
Packing Group

15. Regulatory Information

EU Regulations

Hazard Symbol(s) : -
Risk Phrases : This product is not classified according to the EU regulations.
Safety Phrases : Not applicable.

US Regulations

Haz-Com Standard : Not controlled under the HCS (United States).
EPA : Not available.
State : Not available.

Canadian Regulations

WHMIS : Not controlled under WHMIS (Canada).
CEPA : No products were found.
Provincial : No products were found.

16. Other Information

Validated by map on 10/17/2003.

Version : 1.0
Date of Printing : 10/20/2003.

Notice to Reader

*To the best of our knowledge, the information contained herein is accurate. However, neither the above named supplier nor any of its subsidiaries assumes any liability whatsoever for the accuracy or completeness of the information contained herein. Final determination of suitability of any material is the sole responsibility of the user. All materials may present unknown hazards and should be used with caution. Although certain hazards are described herein, we cannot guarantee that these are the only hazards that exist. **This product is intended for research use only.***

Material Safety Data Sheet

Canada
English

Section 1. Chemical product and company identification

Product name

pGEX-6P-1 Vector, 25 µg

Catalogue Number

28-9546-48



Material uses

Industrial applications: Analytical chemistry. Research.

Product type

Liquid.

Validation date

16 April 2009

Print date

16 April 2009

Supplier

GE Healthcare UK Ltd
Amersham Place
Little Chalfont
Buckinghamshire HP7 9NA
England
+44 0870 606 1921

In case of emergency

US	ChemTrec (US)	1-800-424-9300
Canada	ChemTrec (US)	1-703-527-3887

2. Hazards identification

Physical state

Liquid.

Odor

Odorless.

Emergency overview

No specific hazard.

NOT EXPECTED TO PRODUCE SIGNIFICANT ADVERSE HEALTH EFFECTS WHEN THE RECOMMENDED INSTRUCTIONS FOR USE ARE FOLLOWED.

No known significant effects or critical hazards. Avoid prolonged contact with eyes, skin and clothing.

Routes of entry

Dermal contact. Eye contact. Inhalation. Ingestion.

Potential acute health effects

Eyes

No known significant effects or critical hazards.

Skin

No known significant effects or critical hazards.

Inhalation

No known significant effects or critical hazards.

Ingestion

No known significant effects or critical hazards.

Potential chronic health effects

Chronic effects

No known significant effects or critical hazards.

Carcinogenicity

No known significant effects or critical hazards.

Mutagenicity

No known significant effects or critical hazards.

Teratogenicity

No known significant effects or critical hazards.

Developmental effects

No known significant effects or critical hazards.

Fertility effects

No known significant effects or critical hazards.

Target organs

Not available.

Inhalation

No specific data.

Ingestion

No specific data.

Skin

No specific data.

Eyes

No specific data.

Medical conditions aggravated by over-exposure

None known.

See toxicological information (section 11)



Article Number

28954648



Page: 1/4

Validation date 16 April 2009

potentially contaminated clothing. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.

Personal protection

Respiratory	Use a properly fitted, air-purifying or air-fed respirator complying with an approved standard if a risk assessment indicates this is necessary. Respirator selection must be based on known or anticipated exposure levels, the hazards of the product and the safe working limits of the selected respirator.
Hands	Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary.
Eyes	Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists or dusts.
Skin	Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.
Environmental exposure controls	Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

Section 9. Physical and chemical properties

Physical state	Liquid.
Color	Colorless.
Odor	Odorless.
pH	7.5 (Conc. (% w/w): 100%)
Volatility	0% (v/v)
VOC	0 (g/l).
Solubility	Easily soluble in the following materials: cold water and hot water.

Section 10. Stability and reactivity

Stability	The product is stable.
Materials to avoid	No specific data.
Hazardous polymerization	Under normal conditions of storage and use, hazardous polymerization will not occur.
Conditions of reactivity	Non-flammable in the presence of the following materials or conditions: open flames, sparks and static discharge, heat, shocks and mechanical impacts, oxidizing materials, reducing materials, combustible materials, organic materials, metals, acids, alkalis and moisture. Not considered to be a product presenting a risk of explosion.

Section 11. Toxicological information

Acute toxicity

Product/ingredient name	Result	Species	Dose	Exposure
Not available.				

Conclusion/Summary Not available.

Classification

Product/ingredient name	ACGIH	IARC	EPA	NIOSH	NTP	OSHA
Not available.						

Synergistic products Not available.

Section 12. Ecological information

Environmental effects	No known significant effects or critical hazards.
Octanol/water partition coefficient	Not available.
Bioconcentration factor	Not available.
Other adverse effects	No known significant effects or critical hazards.

Section 13. Disposal considerations

Waste disposal	The generation of waste should be avoided or minimized wherever possible. Empty containers or liners may retain some product residues. This material and its container must be disposed of in a safe way. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers.
RCRA classification	Not available.

Disposal should be in accordance with applicable regional, national and local laws and regulations.



Section 14. Transport information

International transport regulations

Not classified.

Section 15. Regulatory information

WHMIS (Canada) Not controlled under WHMIS (Canada).
Canadian lists **CEPA Toxic substances:** None of the components are listed.
Canadian ARET: None of the components are listed.
Canadian NPRI: None of the components are listed.
Alberta Designated Substances: None of the components are listed.
Ontario Designated Substances: None of the components are listed.
Quebec Designated Substances: None of the components are listed.
Canada inventory All components are listed or exempted.

This product has been classified in accordance with the hazard criteria of the Controlled Products Regulations and the MSDS contains all the information required by the Controlled Products Regulations.

EU regulations

Hazard symbol or symbols

Risk phrases This product is not classified according to EU legislation.
Safety phrases Not applicable.

International regulations

International lists **Australia inventory (AICS):** All components are listed or exempted.
China inventory (IECSC): All components are listed or exempted.
Japan inventory (ENCS): All components are listed or exempted.
Japan inventory (ISHL): Not determined.
Korea inventory (KECI): All components are listed or exempted.
New Zealand Inventory of Chemicals (NZIoC): All components are listed or exempted.
Philippines inventory (PICCS): All components are listed or exempted.

Section 16. Other information



The customer is responsible for determining the PPE code for this material.
Indicates information that has changed from previously issued version.

History

Date of printing	16 April 2009	Date of previous issue	16 April 2009
Date of issue	16 April 2009	Version	1

Notice to reader

To the best of our knowledge, the information contained herein is accurate. However, neither the above-named supplier, nor any of its subsidiaries, assumes any liability whatsoever for the accuracy or completeness of the information contained herein. Final determination of suitability of any material is the sole responsibility of the user. All materials may present unknown hazards and should be used with caution. Although certain hazards are described herein, we cannot guarantee that these are the only hazards that exist.



Clone: HsCD00004370

Clone ID: HsCD00004370 Type: cDNA
 Verified: Y Verification Method: Sequence Verification
 Status: AVAILABLE Distribution: No restriction
 Source: HIP Special MTA:
 Description:
 Comments:
 Map: [pDNR-Dual_with_human_insert.pdf](#)

Related Identifiers:

Original Clone ID FLH013476.01X
 HIP Clone ID [13476](#)
 GI [61361493](#)
 GenBank Accession [AY890114](#)
 HIP Master Clone ID 27675

Property:

Collection Breast Cancer 1000

Insert Information:

Insert	Size (bp)	Species	Mutation	Discrepancy	Format	Tissue Source	Species Specific ID	Gene Symbol	Gene Name	Target Genbank	Keyword
	282	Homo sapiens	No	No	CLOSED	MGC template	6279	S100A8	S100 calcium binding protein A8 (calgranulin A)	BC005928	

Insert Sequence:

Insert: 1

```
ATGTTGACCGAGCTGGAGAAAGCCTTGAACCTATCATCGACGTCTACCACAAGTACTCC
CTGATAAAGGGGAATTTCCATGCCGTCTACAGGGATGACCTGAAGAAATTGCTAGAGACC
GAGTGTCTCAGTATATCAGGAAAAAGGTTGCAGACGTCTGGTTCAAAGAGTTGGATATC
AACACTGATGGTGCAGTTAACTTCCAGGAGTTCTCATTCTGGTGATAAAGATGGGCGTG
GCAGCCACAAAAAAGCCATGAAGAAAGCCACAAAGAGTAG
```

Insert Property: Insert 1

Type	Value	Extra Information
End on reference sequence	337	
Start on reference sequence	56	

Vector Information:

Vector Name: [pDNR-Dual](#) Size (bp): 4938
 Type: bacterial plasmid Form: dsDNA
 Description: Recombinational donor/master vector with 6xHN tag ORF, T7 and M13 primer sites; ampicillin resistance; restriction enzyme cloning (into) and recombinational cloning (from).
 Properties: Creator, donor (entry), loxP, multiple cloning site, recombinational cloning, with tag/fusion/marker
 Comments: The position of features were determined for the empty form of the vector, which is described in detail on the BD/Clontech website. Subcloning into the MCS was performed using the infusion reaction strategy and some restriction sites in the MCS may be lost after an insert is added.
 Map: [pDNR-Dual.pdf](#)

Sequence: [pDNR-Dual FASTA.txt](#)

Host Information:

Host Strain	Is Used In Distribution	Description
DH5- α T1 phage resistant	Y	

Antibiotic Selections:

Host Type	Marker
bacterial	ampicillin

Recommended Growth Condition:

Host Type	Selection Condition	Growth Condition	Comments
bacterial	100 ug/mL ampicillin	Growth with the single antibiotic in LB at 37 degrees is recommended.	Commonly used conditions for ampicillin resistant plasmid clones.

Authors:

Author Name	Author Type
HIP	Academic Institute

Publications:

PMID	Title
16512675	Functional proteomics approach to investigate the biological activities of cDNAs implicated in breast cancer.

Clone: HsCD00005454

Clone ID: HsCD00005454 Type: cDNA
 Verified: Y Verification Method: Sequence Verification
 Status: AVAILABLE Distribution: No restriction
 Source: HIP Special MTA:

Description:
 Comments:
 Map:

Related Identifiers:

HIP Clone ID 131119
 Original Clone ID FLH131119.01X
 GI 60822416
 GenBank Accession AY693569
 HIP Master Clone ID 107276

Property:

Collection Breast Cancer 1000

Insert Information:

Insert	Size (bp)	Species	Mutation	Discrepancy	Format	Tissue Source	Species Specific ID	Gene Symbol	Gene Name	Target Genbank	Keyword
	345	Homo sapiens	No	No	CLOSED	1st strand cDNA from placenta and brain	<u>6280</u>	S100A9	S100 calcium binding protein A9 (calgranulin B)	<u>X06233</u>	

Insert Sequence:

Insert: 1

```
ATGACTTGCAAAATGTCGCAGCTGGAACGCAACATAGAGACCATCATCAACACCTTCCAC
CAATACTCTGTGAAGCTGGGGCACCCAGACACCCTGAACCAGGGGAATTCAAAGAGCTG
GTGCGAAAAGATCTGCAAAATTTTCTCAAGAAGGAGAATAAGAATGAAAAGGTCATAGAA
CACATCATGGAGGACCTGGACACAAATGCAGACAAGCAGCTGAGCTTCGAGGAGTTCATC
ATGCTGATGGCGAGGCTAACCTGGGCCTCCCACGAGAAGATGCACGAGGGTGACGAGGGC
CCTGGCCACCACCATAAGCCAGGCCTCGGGAGGGCACCCCTAA
```

Insert Property: Insert 1

Type	Value	Extra Information
End on reference sequence	389	
Start on reference sequence	45	

Vector Information:

Vector Name: pDONR201 Size (bp): 4470
 Type: bacterial plasmid Form: dsDNA
 Description: Recombinational donor/master vector; kanamycin resistance; recombinational cloning.
 Properties: Gateway, donor (entry), recombinational cloning
 Comments: The position of features were determined for the unrecombined (empty) form of the vector, which is described in detail on the Invitrogen website.

Map: [pdonr201_pdonr207_map.pdf](#)

Sequence: [pDONR201_FASTA.txt](#)

Host Information:

Host Strain	Is Used In Distribution	Description
DH5-alpha T1 phage resistant	Y	

Antibiotic Selections:

Host Type	Marker
bacterial	kanamycin

Recommended Growth Condition:


Host Type	Selection Condition	Growth Condition	Comments
bacterial	50ug/mL kanamycin	Growth with the single antibiotic in LB at 37 degrees is recommended.	Conditions for Gateway-type vectors in recombined (with insert) form and other kanamycin resistant vectors.

Authors:

Author Name	Author Type
HIP	Academic Institute

Publications:

PMID	Title
------	-------



Welcome, Kathy Barber | [View Cart](#) | [Account](#) | [Logout](#)

Search for Plasmids:



[Advanced Search](#)

[Plasmid Cart](#)

Your cart is empty.

[Browse](#) > [Yue Xiong](#) > [He et al](#) > pCDNA3-myc3-ROC1

[Print Friendly](#) [Email](#)



Price: \$65.00

Plasmid 20717: pCDNA3-myc3-ROC1

RING finger protein 1 (ROC1)
 ROC1, RNF75, RBX1
 RBX1 ring-box 1
 Regulator of Cullins 1
 323
 AF142059
 RBX1, ROC1, RNF75, MGC1481,
 MGC13357, BA554C12.1
 H. sapiens (human)
 myc3
 N terminal on backbone
 pcDNA3
 ([Search Vector Database](#))
 Invitrogen
 Mammalian expression
 4620
 KpnI
 No
 XhoI
 No
 T7 ([List of Sequencing Primers](#))
 SP6
 Ampicillin
 High Copy
 Yes
 G418
[View sequence](#)
[View map](#)
 DH5a
 Yue Xiong
[MTA](#)

Author's map
Sequence
Reviews (0)
From this article
RBX1 plasmids
Yue Xiong Lab Plasmids
AF142059
NCBI: RBX1
RBX1 antibodies

Recently Viewed


pCDNA3-myc3-ROC1
 Plasmid 20717

pcDNA3-HA2-CUL4A
pcDNA3-FLAG-DDB1
pcDNA3-HA-ROC2

Addgene has sequenced a portion of this plasmid for verification. Click [here](#) for the sequencing result.

[Click on map to enlarge](#)

Protein expression.



DDB1 functions as a linker to recruit receptor WD40 proteins to CUL4-ROC1 ubiquitin ligases. He YJ et al. (Genes Dev. 2006 Nov 1. 20(21):2949-54. [Pubmed](#))

Please acknowledge the principal investigator and cite this article if you use this plasmid in a publication.

Also, please include the text "Addgene plasmid 20717" in your Materials and Methods section. This information allows Addgene to create a link from the plasmid page to your publication.

Welcome To PlasmID

Protein Structure Initiative - Material Repository (PSI-MR)

 [VIEW CART](#)

[Sign Out](#) | [My Account](#) | [FAQ](#)

[Home](#)

[Plasmid Submission](#)

[Search & Order](#)

[Contact Us](#)

Home

[Home](#) > [My Account](#) > [Order History](#)

- [My Account](#)
- [Update Account](#)
- [View Orders](#)
- [View Containers](#)
- [Vector Submission](#)
- [Vector for Distribution](#)

Order History

View the order history and detailed order information

Order ID: 3478


1	HsCD00004370 cDNA	6279	S100A8	S100 calcium binding protein A8 (calgranulin A)	BC005926	No/No	CLOSED	pDNR-Dual	bacterial; ampicillin;
2	HsCD00005454 cDNA	6280	S100A9	S100 calcium binding protein A9 (calgranulin B)	X05233	No/No	CLOSED	pUCNR201	bacterial; kanamycin;

[Download Clone List](#)

[Plasmid Submission](#)

©2004-2009 Harvard Institute of Proteomics

Protein expression.

[Gene Synthesis](#)[Expression Optimization](#)[Libraries](#)[Scientific Resources](#)[Company](#)[My Account](#)[Overview](#)[Expression Guarantee](#)[Synthetic Gene
Expression](#)[Design Parameters](#)[Optimized Genes](#)[Host Systems](#)[Expression Vectors](#)[Place Order or Request Quote](#)


Protein Expression Vectors

Vectors for bacterial expression

DNA2.0 synthetic genes are available in vectors that are immediately usable for bacterial protein expression. Cloning into these vectors is performed at no additional cost and the constructs are provided without IP restrictions. DNA2.0 can even guarantee that your gene will express.

pJexpress vectors transcribe from promoters that are repressed by flanking copies of the lac operator. The vectors also carry a copy of the lacI gene, which expresses the repressor protein that binds to the lac operator.

pJexpress Vector Map



pJexpress Features

- Higher level of protein expression than pET vectors when using the same insert (see gel below).
- Choose between ampicillin, kanamycin, chloramphenicol and zeocin resistances
- 'IP-free'. The T5 promoter sequence was described in 1985 (Gentz and Bujard (1985) J. Bacteriol **164**,70) and we have not patented our modifications. pJexpress vectors with T5 promoter can be induced by IPTG in any *E. coli* host.
- Silencing of the promoter prior to IPTG induction is achieved using symmetrical lac operators (Sadler *et al* (1983) Proc Natl Acad Sci USA **80**:6785) spaced around the promoter to maximize cooperativity (Oehler *et al* (1994) EMBO J **13**:3348). This operator pair ensures significantly tighter repression than regular lac operators. Overlapping T5 promoter/lac operator has been described (Lanzer and Bujard 1988 Proc Natl Acad Sci USA **85**:8973).
- Customize your own ribosome binding site (RBS), have us design one for you or use the default RBS tested in gel below (AGGAGGTA AACAT).

pJexpress vectors are currently available with the following options

Vector	Features
pJexpress 401	T5 promoter ^A , Kan ^r , pUC origin ^C

Protein Variant Libraries

DNA2.0 has developed 6 dynamic Library options to enable you to modify the activities of proteins or regulatory regions of DNA.

[Explore Libraries](#)

DNA2.0 Wins Award

The Scientist heralds DNA2.0's Gene Design Algorithm a "Top 10 Innovation"



DNA2.0 Optimization Technology named among "The ten most exciting tools to hit the life sciences this year."

[Read Now](#)

pJexpress 402	T5 promoter ^A , Zeo ^r , pUC origin ^C
pJexpress 404	T5 promoter ^A , Amp ^r , pUC origin ^C
pJexpress 406	T5 promoter ^A , Kan ^r , Amp ^r , Clm ^r , pUC origin ^C
pJexpress 411	T7 promoter ^B , Kan ^r , pUC origin ^C
pJexpress 412	T7 promoter ^B , Zeo ^r , pUC origin ^C
pJexpress 414	T7 promoter ^B , Amp ^r , pUC origin ^C
pJexpress 416	T7 promoter ^B , Kan ^r , Amp ^r , Clm ^r , pUC origin ^C

^A We have modified the T5 promoter to give even higher protein expression levels; it is repressible, and works in any *E. coli* strain.

^B The T7 promoter results in high protein expression levels and is repressible. The T7 promoter only works in T7 pol expressing *E. coli* strains (eg. BL21(DE3) or T7 Express). Note that strains in which basal expression is reduced, such as those carrying *lysS* or *lysY*, frequently express to lower levels after induction when compared with strains that carry only the T7 polymerase gene. Use of host cells that may contain the cloned copy of the T7 gene 1, the gene for T7 RNA polymerase with any other vector(s) containing a T7 promoter to direct the production of RNA or protein requires a license from Brookhaven National Laboratory. Information about research-use or commercial-use license agreements may be obtained from the Office of Intellectual Property and Sponsored Research, Brookhaven National Laboratory, Building 475D, P.O. Box 5000, Upton, New York, 11973-5000; telephone: 631-344-7134; fax: 631-344-3729.

^C pUC origin of replication results in high copy number plasmid.

For PCR or sequencing primers flanking the insert we use the following oligonucleotides:

pTF 5'-CTCGAAAATAATAAAGGGAAAATCAG-3'


pTR 5'-TGGTAGTGTGGGACTC-3'

Please note: The pJ vectors do not contain restriction sites for excision of your gene. These must be included in your gene design if you wish to remove your gene with restriction enzymes.

pJexpress Tags

pJexpress vectors do not come with built in tags for affinity purification or solubility enhancement. Any tag (plus any protease cleavage site for tag removal) can be added very cost effectively at either the N- or C-terminus during synthesis.

Protein Expression from pJexpress



Genes encoding a single chain antibody (ScFv ~30 kDa), a DNA polymerase (polymerase ~65 kDa), or a fluorescent protein (FP ~30 kDa) were designed using DNA2.0's algorithms for codon optimization to express in *E. coli*. The genes were cloned into pJexpress401 or pET28 then transformed into an *E. coli* host for expression. Genes in pJexpress401 were transformed into standard cloning strain DH10B; genes in pET28 were transformed into a

host strain expressing T7 RNA polymerase, in this case BL21(DE3)-pLysS. One colony of each construct was picked and grown in 3 ml LB containing the appropriate antibiotic (in this case 25 µg/ml kanamycin). Cells were grown at 37°C with shaking until they had reached an A_{600} between 0.6 and 1.0. An aliquot of culture (1 ml) was then taken into 3 ml of LB containing antibiotic plus 1 mM IPTG, and grown for a further 4 hours. At this time, samples (50 µl) were taken from uninduced (-) and IPTG induced (+) cultures. SDS sample buffer was added, and the samples were heated at 99°C for 10 minutes and the equivalent of 2 µl of culture was run on a 10% polyacrylamide gel.